Resultado de búsqueda
13 de nov. de 2019 · Cold agglutinin disease (CAD) is a rare autoimmune hemolytic anemia (AIHA) accounting for 20% of all cases, with no approved therapies and limited management options for patients. CAD is characterized by immunoglobulin M-mediated erythrocyte agglutination, which triggers activation of the classical complement pathway leading to ...
15 de ago. de 2013 · The thermal amplitude of the cold agglutinin antibody in many patients is such that physiologic peripheral cooling results in antibody binding sufficient to cause anemia. 52 Supportive transfusions may be used in patients with severe anemia.
1 de abr. de 2024 · Cold agglutinin disease (CAD) is a form of autoimmune hemolytic anemia (AIHA) in which cold agglutinins (IgM autoantibodies against red blood cell [RBC] antigens that bind at cold temperatures) can cause clinical symptoms related to RBC agglutination in cooler parts of the body and hemolytic anemia. This topic reviews the ...
11 de mar. de 2021 · The last decades have seen great progress in the treatment of cold agglutinin disease (CAD). Comparative trials are lacking, and recommendations must be based mainly on nonrandomized trials and will be influenced by personal experience. Herein, current treatment options are reviewed and linked to 3 cases, each addressing specific ...
the spread of HIV is heterosexual transmission, blood transfusion is the most efficient mechanism. It is estimated that the transmission of HIV through blood transfusion is more than 90% efficient. Preventing the spread of HIV through blood and blood products is, however, a goal that can be attained by every national blood programme.
For symptomatic patients and those that are transfusion dependent a trial of rituximab plus bendamustine should be considered a first-line consideration in the management of cold agglutinin hemolytic anemia.
Transfusions were required in 65% of the cohort, with a mean of 11 transfusions per patient-year. 8 In a review of medical claims records, 31% of patients with cold agglutinin disease had a medical claim for a thromboembolism compared with 20% in the matched group. 6
